Pasuchaca (Geranium dielsianum)

Pasuchaca (Geranium dielsianum) is an Amazonian herb that demonstrates potent α-glucosidase inhibition with 96% maltase inhibition at tested concentrations. The plant shows blood sugar regulation potential through enzymatic inhibition and advanced glycation end-product protection via methylglyoxal scavenging.

Origin & History

Pasuchaca (Geranium dielsianum Knuth) is a small perennial herb native to Peru that grows 3-6 cm tall with distinctive 7-lobed palmate leaves. The aerial parts are harvested and typically extracted using 80% methanol or hydrated ethanol methods, yielding concentrated dihydroflavonol glycosides, particularly astilbin.

Historical & Cultural Context

Pasuchaca has been used in Peruvian traditional medicine for diabetes management, blood purification, and treating conditions like chronic diarrhea, hemorrhages, and inflammation. While described as a longstanding remedy by Laboratorios Fitofarma, the specific historical duration of use is undocumented.

Health Benefits

• Blood sugar regulation support through α-glucosidase inhibition (96% maltase inhibition at tested concentrations, IC50 0.028 mg/mL) - preliminary evidence only
• Protection against advanced glycation end-products (AGEs) through methylglyoxal scavenging - in vitro studies show superior performance to aminoguanidine
• Antioxidant activity from phenolic compounds (314-406 mg GAE/g dry matter) - preliminary evidence
• Traditional use for pancreatic health and hypoglycemia management - no clinical validation
• Anti-inflammatory potential based on traditional applications - no scientific evidence available

How It Works

Pasuchaca exerts its effects primarily through α-glucosidase enzyme inhibition, specifically targeting maltase with an IC50 of 0.028 mg/mL. The herb's bioactive compounds also scavenge methylglyoxal, a reactive dicarbonyl that forms advanced glycation end-products (AGEs). This dual mechanism supports glucose metabolism regulation and prevents protein glycation damage.

Scientific Research

No human clinical trials have been conducted on Pasuchaca. Available evidence is limited to in vitro studies, including one showing antiglycation activity where astilbin inhibited protein glycation across all stages (PMID: 41376105). Other laboratory studies demonstrated maltase inhibition and α-glucosidase inhibition, but human efficacy remains unproven.

Clinical Summary

Current evidence for Pasuchaca is limited to preliminary in vitro studies demonstrating enzymatic inhibition and antioxidant properties. Laboratory testing shows 96% maltase inhibition at specific concentrations, with superior methylglyoxal scavenging compared to control compounds. No human clinical trials have been conducted to validate these preliminary findings. The evidence remains at the preclinical stage and requires human studies for therapeutic confirmation.

Nutritional Profile

{"macronutrients": {"fiber": "Not specified", "protein": "Not specified"}, "micronutrients": {"vitamins": "Not specified", "minerals": "Not specified"}, "bioactive_compounds": {"phenolic_compounds": "314-406 mg GAE/g dry matter", "methylglyoxal_scavengers": "Present, specific concentration not specified"}, "bioavailability_notes": "Bioavailability of phenolic compounds and methylglyoxal scavengers not specified"}

Preparation & Dosage

No clinically studied human dosages exist. In vitro studies used extract concentrations of 0.00025-0.0005 mg/mL for enzyme inhibition, with astilbin content reaching 252.41 mg/g in 80% methanol extracts. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Cinnamon extract, Chromium picolinate, Alpha-lipoic acid, Gymnema sylvestre, Bitter melon

Safety & Interactions

Safety data for Pasuchaca supplementation is extremely limited due to lack of human studies. No established side effect profile, drug interactions, or contraindications have been documented in scientific literature. Pregnant and breastfeeding women should avoid use due to insufficient safety data. Individuals taking diabetes medications should consult healthcare providers before use due to potential additive blood sugar lowering effects.